(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) slid by a staggering 20.69% in 10 sessions from €0.87 to €0.69 at 13:57 EST on Thursday, after three consecutive sessions in a row of losses. CAC 40 is rising 0.85% to €6,944.48, following the last session’s downward trend.
ERYTECH PHARMA’s last close was €0.68, 70.04% below its 52-week high of €2.26.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-3.99.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ERYTECH PHARMA’s stock is considered to be overbought (>=80).
Volatility
ERYTECH PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.28%, a negative 1.49%, and a positive 6.18%.
ERYTECH PHARMA’s highest amplitude of average volatility was 4.78% (last week), 4.27% (last month), and 6.18% (last quarter).
More news about ERYTECH PHARMA (ERYP.PA).
